CD274 and neoplasm: More recently, immunotherapy approaches (e.g., monoclonal antibodies against programmed death-ligand (PD-L1)) have made inroads into the breast oncology space, particularly for the treatment of TNBCs due to their higher mutational burden, higher infiltration of tumor lymphocytes, and higher expression of PD-L1 [7].